Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed

Updated 06/21/2024

Status Not yet recruiting

Clinical Trial Summary

This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05949931
Study type	Interventional
Source	Sun Yat-sen University
Contact	Qingqing Cai, MD. PhD.
Phone	0086-20-87342823
Email	caiqq@sysucc.org.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	August 2023
Completion date	December 2026

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03233347` - Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma	Phase 2
	Active, not recruiting	`NCT03712202` - Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma	Phase 2
	Recruiting	`NCT05833984` - Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas	Phase 1/Phase 2
	Active, not recruiting	`NCT02758717` - Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma	Phase 2
	Active, not recruiting	`NCT01771107` - Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma	Phase 1/Phase 2
	Active, not recruiting	`NCT02166463` - Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma	Phase 3
	Completed	`NCT00654732` - Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma	Phase 2
	Active, not recruiting	`NCT04788043` - Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma	Phase 2
	Not yet recruiting	`NCT06465446` - A Study of IMM01 in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma	Phase 3
	Recruiting	`NCT05955105` - A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies	Phase 1/Phase 2
	Completed	`NCT06235047` - Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
	Recruiting	`NCT06164275` - Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	Phase 2
	Active, not recruiting	`NCT05179603` - A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]	Phase 2
	Active, not recruiting	`NCT03907488` - Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma	Phase 3
	Not yet recruiting	`NCT06377540` - MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma	Phase 2
	Active, not recruiting	`NCT03057795` - Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma	Phase 2